Marc Thill
- Cancer Research top 2%
- Breast Cancer Treatment Studies 58
- Oncology top 2%
- HER2/EGFR in Cancer Research 28
- Cancer Treatment and Pharmacology 26
-
- Vitamin D Research Studies 18
- Breast Lesions and Carcinomas 18
-
- Advanced Breast Cancer Therapies 41
- Reproductive Medicine top 5%
-
- Estrogen and related hormone effects 19
-
- Breast Implant and Reconstruction 16
Marc Thill
151 papers receiving 2.3k citations
Hit Papers
Peers
Comparison fields: 5 of 113
- Cancer Research 889
- Oncology 1.1k
- Pathology and Forensic Medicine 518
- Pulmonary and Respiratory Medicine 507
- Reproductive Medicine 107
Countries citing papers authored by Marc Thill
This map shows the geographic impact of Marc Thill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Thill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Thill more than expected).
Fields of papers citing papers by Marc Thill
This network shows the impact of papers produced by Marc Thill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Thill. The network helps show where Marc Thill may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Marc Thill, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 6 | |
| 3 | 2024 | 5 | |
| 4 | 2023 | 10 | |
| 5 | Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studybreakdown → | 2022 | 204 |
| 6 | 2022 | 2 | |
| 7 | 2021 | 15 | |
| 8 | 2021 | 1 | |
| 9 | 2019 | 8 | |
| 10 | 2017 | 1 | |
| 11 | 2016 | 121 | |
| 12 | 2016 | 3 | |
| 13 | 2016 | 7 | |
| 14 | 2016 | 4 | |
| 15 | 2016 | 7 | |
| 16 | 2015 | 12 | |
| 17 | 2014 | 34 | |
| 18 | 2014 | 20 | |
| 19 | 2013 | 3 | |
| 20 | 2009 | 2 |
About Marc Thill
Marc Thill is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 163 papers that have together received 2.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (58 papers), Advanced Breast Cancer Therapies (41 papers), HER2/EGFR in Cancer Research (28 papers), Cancer Treatment and Pharmacology (26 papers), Estrogen and related hormone effects (19 papers), Vitamin D Research Studies (18 papers), Breast Lesions and Carcinomas (18 papers) and Breast Implant and Reconstruction (16 papers). The work is most often cited by research in Cancer Research (889 citations), Oncology (1.1k citations) and Pathology and Forensic Medicine (518 citations). Marc Thill has collaborated with scholars based in Germany, Switzerland and Italy. Frequent co-authors include Cornelia Liedtke, Marcus Schmidt, C. Dittmer, S. Nitschmann, Dorothea Fischer, Klaus Diedrich, Michael Friedrich, Friederike Hoellen, Kristin Baumann and Steffi Becker. Their work appears in journals such as Breast Care, Cancer Research, Archives of Gynecology and Obstetrics, Journal of Clinical Oncology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.